- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT06512311
Terapie mirate personalizzate per il glioblastoma mediante screening farmacologico ex vivo (ATTRACT)
Terapie mirate personalizzate per il glioblastoma mediante screening farmacologico ex vivo: sperimentazione clinica avanzata su tumori cerebrali TheRApy (ATTRACT)
Patient derived cell line (PDC) -based drug screening will be applied to formulate a personalized treatment approach.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Patient derived cell line (PDC) -based drug screening will be applied to formulate a personalized treatment approach. Patients will be randomized between the investigational group receiving in addition to standard histology analysis also the PDC-based drug screening and the standard group receiving only standard histology analysis. Outcome results will be compared in a randomized, interventional clinical performance study. The PDC-based drug screening will be performed only in accordance with the approved Performance Study Plan on subjects who have signed an informed consent form.
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
State of Vienna
-
Vienna, State of Vienna, Austria, 1090
- Reclutamento
- AKH Vienna, Department for Internal Medicine I, Oncology
-
Contatto:
- Marika Rosner
- Numero di telefono: 44450 +43140400
- Email: marika.rosner@meduniwien.ac.at
-
Contatto:
- Anna Berghoff, MD
- Numero di telefono: 44450 +43140400
- Email: anna.berghoff@meduniwien.ac.at
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Age 18-75
- ECOG performance status 0-2
- Newly diagnosed glioblastoma, IDH wildtype - according to the 2021 WHO classification of Tumors of the Central Nervous System
- MGMT promotor unmethylated per local investigator
- Tissue available for drug screening (successful PDC establishment from surgical material)
- Scheduled for concomitant radio-chemotherapy with temozolomide
- Written informed consent
Exclusion Criteria:
-
Current participation in another therapeutic clinical trial
-
Patients with a concurrent malignancy or malignancy within five years prior of study enrolment except for carcinoma in situ of the cervix, non-melanoma skin carcinoma or stage I uterine cancer within the last 3 years
-
Pregnant or lactating women
-
Current known infection with hepatitis B virus (HBV), or hepatitis C virus (HCV). Patients with past HBV infection or resolved HBV infection (defined as having a negative hepatitis B surface antibody [HBsAg] test and a positive anti-hepatitis B core antibody [HBcAb] test, accompanied by a negative HBV DNA test) are eligible. Patients positive for anti-HCV antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.
-
Known human immunodeficiency virus (HIV) infection that is not well controlled. All of the following criteria are required to define an HIV infection that is well controlled: undetectable viral RNA, CD4+ count ≥350 cells/mm3 , no history of AIDS-defining opportunistic infection within the past 12 months, and stable for at least 4 weeks on the same anti-HIV medications (meaning there are no expected further changes in that time to the number or type of antiretroviral drugs in the regimen). If an HIV infection meets the above criteria, monitoring of viral RNA load and CD4+ count is recommended.
-
Any of the following co-morbidities:
- Pre-existing severe peripheral neuropathy (> CTCAE grade 2)
- Hepatic impairment (Bilirubin Level >1.5x-3x ULN)
- Kidney dysfunction (CrCl < 59 mL/min)
- Cardiac dysfunction with left ventricular ejection fraction <60 %
- Any grade of interstitial lung disease
- Ongoing or previous history of rhabdomyolysis
- Acute pancreatitis
- QTcF ≥480 msec
- Diabetes mellitus with fasting glucose > 250mg/dl or 13.9 mmol/L
-
Participants who are unable or unwilling to comply with the requirements of the protocol as assessed by the investigator.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Altro
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: PDC-based drug screening
120 patients will be included in the intervention group and will receive PDC-based drug screening. The molecular tumor board will formulate a personalized treatment recommendation by incorporating the individual characteristics of the patients including age, co-morbidities, co-medication, and performance status in addition to the results of the PDC-based drug screening. |
The main devices used within the drug screening process are purchased from PerkinElmer, Liconic Instruments, BioTek and Beckman Coulter Diagnostics. |
|
Nessun intervento: Standard group
120 patients will be included in the standard group and will not receive PDC-based drug screening. In line, no personalized treatment approach will be formulated by the molecular tumor board and patients will all receive the recommendation for standard treatment including temozolomide maintenance therapy for 6 cycles. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Overall survival time
Lasso di tempo: From date of randomization until date of death from any cause or last follow up whichever came first, assessed up to 144 months
|
Change in overall survival in patients receiving extensive diagnostic work up including the standard histology analysis and PDC- based drug screening in addition (interventional arm) compared to patients receiving only standard histology diagnostic work up (standard arm) |
From date of randomization until date of death from any cause or last follow up whichever came first, assessed up to 144 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Feasibility of PDC-based drug screening
Lasso di tempo: From date of randomization until date of communication of the tumor board outcome, asses up to 144 months
|
Number not interpretable results of the PDC-based drug screening; Number of interpretable results of the PDC-based drug screening |
From date of randomization until date of communication of the tumor board outcome, asses up to 144 months
|
|
Comparison of Quality of life measurements
Lasso di tempo: From date of randomization until date of death from any cause or last follow up whichever came first, assessed up to 144 months
|
Difference between the interventional and the standard arm using the European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ- C30) and the brain cancer specific questionnaire (QLQ-BN20). The scale is from 0 to 100, with higher values reporting better quality of life. |
From date of randomization until date of death from any cause or last follow up whichever came first, assessed up to 144 months
|
|
Comparison of neurocognitive function scale
Lasso di tempo: From date of randomization until date of death from any cause or last follow up whichever came first, assessed up to 144 months
|
differences in neurocognitive function between the interventional and standard arms using the Neurologic Assessment in Neuro-Oncology (NANO) scale |
From date of randomization until date of death from any cause or last follow up whichever came first, assessed up to 144 months
|
Collaboratori e investigatori
Sponsor
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- ATTRACT
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .